{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T17:38:36Z","timestamp":1716053916466},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:00:00Z","timestamp":1634601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:00:00Z","timestamp":1634601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s40266-021-00896-w","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T08:14:50Z","timestamp":1634631290000},"page":"1003-1016","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of Oral P2Y12 Inhibitors in Older Patients with Acute Coronary Syndrome: A Frequentist Network Meta-Analysis"],"prefix":"10.1007","volume":"38","author":[{"given":"Izza","family":"Shahid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Abdullah","family":"Nizam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanita","family":"Motiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritesh G.","family":"Menezes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Unaiza","family":"Naeem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tariq Jamal","family":"Siddiqi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tehlil","family":"Rizwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahd","family":"Makhdom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pradhum","family":"Ram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Shariq","family":"Usman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,19]]},"reference":[{"key":"896_CR1","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"M Roffi","year":"2016","unstructured":"Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent st-segment elevation: Task Force For the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:267\u2013315. https:\/\/doi.org\/10.1093\/eurheartj\/ehv320.","journal-title":"Eur Heart J"},{"key":"896_CR2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"M Valgimigli","year":"2018","unstructured":"Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J. 2018;39:213\u201354. https:\/\/doi.org\/10.1093\/eurheartj\/ehx419.","journal-title":"Eur Heart J"},{"key":"896_CR3","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1136\/bmj.38985.646481.55","volume":"333","author":"KAA Fox","year":"2006","unstructured":"Fox KAA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van De Werf F, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ. 2006;333:1091\u20134. https:\/\/doi.org\/10.1136\/bmj.38985.646481.55.","journal-title":"BMJ"},{"key":"896_CR4","doi-asserted-by":"publisher","first-page":"78","DOI":"10.4244\/EIJ-D-16-00497","volume":"13","author":"R Piccolo","year":"2017","unstructured":"Piccolo R, Magnani G, Ariotti S, Gargiulo G, Marino M, Santucci A, et al. Ischaemic and bleeding outcomes in elderly patients undergoing a prolonged versus shortened duration of dual antiplatelet therapy after percutaneous coronary intervention: insights from the PRODIGY randomised trial. EuroIntervention. 2017;13:78\u201386. https:\/\/doi.org\/10.4244\/EIJ-D-16-00497.","journal-title":"EuroIntervention"},{"key":"896_CR5","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001\u201315. https:\/\/doi.org\/10.1056\/NEJMoa0706482.","journal-title":"N Engl J Med"},{"key":"896_CR6","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/nejmoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045\u201357. https:\/\/doi.org\/10.1056\/nejmoa0904327.","journal-title":"N Engl J Med"},{"key":"896_CR7","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/S0140-6736(20)30325-1","volume":"395","author":"M Gimbel","year":"2020","unstructured":"Gimbel M, Qaderdan K, Willemsen L, Hermanides R, Bergmeijer T, de Vrey E, et al. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. Lancet. 2020;395:1374\u201381. https:\/\/doi.org\/10.1016\/S0140-6736(20)30325-1.","journal-title":"Lancet"},{"key":"896_CR8","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777\u201384. https:\/\/doi.org\/10.7326\/M14-2385.","journal-title":"Ann Intern Med"},{"key":"896_CR9","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1093\/eurheartj\/ehr422","volume":"32","author":"RC Becker","year":"2011","unstructured":"Becker RC, Bassand JP, Budaj A, Wojdyla DM, James SK, Cornel JH, et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient outcomes (PLATO) trial. Eur Heart J. 2011;32:2933\u201344. https:\/\/doi.org\/10.1093\/eurheartj\/ehr422.","journal-title":"Eur Heart J"},{"key":"896_CR10","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.2147\/TCRM.S108965","volume":"12","author":"H Wang","year":"2016","unstructured":"Wang H, Wang X. Efficacy and safety outcomes of ticagrelor compared with clopidogrel in elderly Chinese patients with acute coronary syndrome. Ther Clin Risk Manag. 2016;12:1101\u20135. https:\/\/doi.org\/10.2147\/TCRM.S108965.","journal-title":"Ther Clin Risk Manag"},{"key":"896_CR11","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1161\/CIRCULATIONAHA.119.041766","volume":"140","author":"D-W Park","year":"2019","unstructured":"Park D-W, Kwon O, Jang J-S, Yun S-C, Park H, Kang D-Y, et al. Clinically significant bleeding with ticagrelor versus clopidogrel in Korean patients with acute coronary syndromes intended for invasive management. Circulation. 2019;140:1865\u201377. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.041766.","journal-title":"Circulation"},{"key":"896_CR12","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1253\/circj.CJ-13-1482","volume":"78","author":"S Saito","year":"2014","unstructured":"Saito S, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome. Circ J. 2014;78:1684\u201392. https:\/\/doi.org\/10.1253\/circj.CJ-13-1482.","journal-title":"Circ J"},{"key":"896_CR13","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1056\/nejmoa1205512","volume":"367","author":"MT Roe","year":"2012","unstructured":"Roe MT, Armstrong PW, Fox KAA, White HD, Prabhakaran D, Goodman SG, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367:1297\u2013309. https:\/\/doi.org\/10.1056\/nejmoa1205512.","journal-title":"N Engl J Med"},{"key":"896_CR14","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1161\/CIRCULATIONAHA.117.032180","volume":"137","author":"S Savonitto","year":"2018","unstructured":"Savonitto S, Ferri LA, Piatti L, Grosseto D, Piovaccari G, Morici N, et al. Comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization. Circulation. 2018;137:2435\u201345. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.032180.","journal-title":"Circulation"},{"key":"896_CR15","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1056\/nejmoa1908973","volume":"381","author":"S Sch\u00fcpke","year":"2019","unstructured":"Sch\u00fcpke S, Neumann F-J, Menichelli M, Mayer K, Bernlochner I, W\u00f6hrle J, et al. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med. 2019;381:1524\u201334. https:\/\/doi.org\/10.1056\/nejmoa1908973.","journal-title":"N Engl J Med"},{"key":"896_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.11.008","volume":"71","author":"Z Motovska","year":"2018","unstructured":"Motovska Z, Hlinomaz O, Kala P, Hromadka M, Knot J, Varvarovsky I, et al. 1-Year outcomes of patients undergoing primary angioplasty for myocardial infarction treated with prasugrel versus ticagrelor. J Am Coll Cardiol. 2018;71: 371381. https:\/\/doi.org\/10.1016\/j.jacc.2017.11.008.","journal-title":"J Am Coll Cardiol"},{"key":"896_CR17","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.jcma.2016.02.010","volume":"79","author":"IC Chen","year":"2016","unstructured":"Chen IC, Lee CH, Fang CC, Chao TH, Cheng CL, Chen Y, et al. Efficacy and safety of ticagrelor versus clopidogrel in acute coronary syndrome in Taiwan: a multicenter retrospective pilot study. J Chin Med Assoc. 2016;79:521\u201330. https:\/\/doi.org\/10.1016\/j.jcma.2016.02.010.","journal-title":"J Chin Med Assoc"},{"key":"896_CR18","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1253\/CIRCJ.CJ-18-0112","volume":"82","author":"MC Kim","year":"2018","unstructured":"Kim MC, Jeong MH, Sim DS, Hong YJ, Kim JH, Ahn Y, et al. Comparison of clinical outcomes between ticagrelor and prasugrel in patients with ST-segment elevation myocardial infarction: results from the Korea Acute Myocardial Infarction Registry-National Institutes of Health. Circ J. 2018;82:1866\u201373. https:\/\/doi.org\/10.1253\/CIRCJ.CJ-18-0112.","journal-title":"Circ J"},{"key":"896_CR19","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/S40256-019-00373-1","volume":"20","author":"M Peyracchia","year":"2019","unstructured":"Peyracchia M, Saglietto A, Biol\u00e8 C, Raposeiras-Roubin S, Abu-Assi E, Kinnaird T, et al. Efficacy and safety of clopidogrel, prasugrel and ticagrelor in ACS patients treated with PCI: a propensity score analysis of the RENAMI and BleeMACS Registries. Am J Cardiovasc Drugs. 2019;20:259\u201369. https:\/\/doi.org\/10.1007\/S40256-019-00373-1.","journal-title":"Am J Cardiovasc Drugs"},{"key":"896_CR20","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1136\/heartjnl-2014-306925","volume":"101","author":"R Klingenberg","year":"2015","unstructured":"Klingenberg R, Heg D, R\u00e4ber L, Carballo D, Nanchen D, Gencer B, et al. Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland. Heart. 2015;101:854\u201363. https:\/\/doi.org\/10.1136\/heartjnl-2014-306925.","journal-title":"Heart"},{"key":"896_CR21","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1160\/TH08-11-0730","volume":"102","author":"G Palareti","year":"2009","unstructured":"Palareti G, Cosmi B. Bleeding with anticoagulation therapy: who is at risk, and how best to identify such patients. Thromb Haemost. 2009;102:268\u201378. https:\/\/doi.org\/10.1160\/TH08-11-0730.","journal-title":"Thromb Haemost"},{"key":"896_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvaa101","author":"C Montalto","year":"2020","unstructured":"Montalto C, Morici N, Munaf\u00f2 AR, Mangieri A, Mandurino-Mirizzi A, D\u2019Ascenzo F, et al. Optimal P2Y12 inhibition in older adults with acute coronary syndromes: a network meta-analysis of randomized controlled trials. Eur Heart J Cardiovasc Pharmacother. 2020. https:\/\/doi.org\/10.1093\/ehjcvp\/pvaa101.","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"896_CR23","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1160\/TH11-08-0586","volume":"108","author":"S Steiner","year":"2012","unstructured":"Steiner S, Moertl D, Chen L, Coyle D, Wells GA. Network meta-analysis of prasugrel, ticagrelor, high- and standarddose clopidogrel in patients scheduled for percutaneous coronary interventions. Thromb Haemost. 2012;108:318\u201327. https:\/\/doi.org\/10.1160\/TH11-08-0586.","journal-title":"Thromb Haemost"},{"key":"896_CR24","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1161\/CIRCULATIONAHA.120.046786","volume":"142","author":"EP Navarese","year":"2020","unstructured":"Navarese EP, Khan SU, Ko\u0142odziejczak M, Kubica J, Buccheri S, Cannon CP, et al. Comparative efficacy and safety of oral P2Y12 inhibitors in acute coronary syndrome: network meta-analysis of 52 816 patients from 12 randomized trials. Circulation. 2020;142:150\u201360. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.046786.","journal-title":"Circulation"},{"key":"896_CR25","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.ahj.2015.07.009","volume":"170","author":"DJ Kurz","year":"2015","unstructured":"Kurz DJ, Bernheim AM, T\u00fcller D, Zbinden R, Jeger R, Kaiser C, et al. Improved outcomes of elderly patients treated with drug-eluting versus bare metal stents in large coronary arteries: results from the BAsel Stent Kosten-Effektivit\u00e4ts Trial PROspective Validation Examination randomized trial. Am Heart J. 2015;170:787-95.e1. https:\/\/doi.org\/10.1016\/j.ahj.2015.07.009.","journal-title":"Am Heart J"},{"key":"896_CR26","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ijcard.2017.04.079","volume":"243","author":"MC Morice","year":"2017","unstructured":"Morice MC, Talwar S, Gaemperli O, Richardt G, Eberli F, Meredith I, et al. Drug-coated versus bare-metal stents for elderly patients: a predefined sub-study of the LEADERS FREE trial. Int J Cardiol. 2017;243:110\u20135. https:\/\/doi.org\/10.1016\/j.ijcard.2017.04.079.","journal-title":"Int J Cardiol"},{"key":"896_CR27","doi-asserted-by":"publisher","first-page":"643","DOI":"10.5114\/aoms.2014.44855","volume":"10","author":"G Wu","year":"2014","unstructured":"Wu G, Sun G, Zhao R, Sun M. Clinical outcomes of second- versus first-generation drug-eluting stents in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials. Arch Med Sci. 2014;10:643\u201350. https:\/\/doi.org\/10.5114\/aoms.2014.44855.","journal-title":"Arch Med Sci"},{"key":"896_CR28","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1177\/0091270011406280","volume":"52","author":"JS Riesmeyer","year":"2012","unstructured":"Riesmeyer JS, Salazar DE, Weerakkody GJ, Ni L, Wrishko RE, Ernest CS, et al. Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy. J Clin Pharmacol. 2012;52:789\u201397. https:\/\/doi.org\/10.1177\/0091270011406280.","journal-title":"J Clin Pharmacol"}],"container-title":["Drugs &amp; Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-021-00896-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-021-00896-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-021-00896-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T16:08:01Z","timestamp":1636992481000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-021-00896-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,19]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["896"],"URL":"https:\/\/doi.org\/10.1007\/s40266-021-00896-w","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,19]]},"assertion":[{"value":"6 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"None of the authors has any conflicts of interest to disclose, financial or otherwise.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/Competing interests"}},{"value":"All work was conducted in accordance with the Declaration of Helsinki (1964).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"IS: contributed to the study design and conception, data acquisition and analysis, interpretation of data, drafting the manuscript, project administration. MAN: contributed to the study design, data acquisition and analysis, interpretation of data, drafting the manuscript. VM: contributed to data acquisition and interpretation of data, drafting the manuscript. RGM: contributed to the study design, interpretation of data, critically reviewed the manuscript, project administration. UN: contributed to the study design, interpretation of data, critically reviewed the manuscript. TJS: contributed to the study design, interpretation of data, critically reviewed the manuscript. TR: contributed to the study design, interpretation of data, critically reviewed the manuscript. FM: contributed to the study design, interpretation of data, critically reviewed the manuscript. PR: contributed to the study design, interpretation of data, critically reviewed the manuscript. MSU: contributed to the study design and conception, project administration, interpretation of data, critically reviewed the manuscript","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}